Modulating the gut microbiota and inflammation is involved in the effect of diosgenin against diabetic nephropathy in rat

Modulating the gut microbiota and inflammation is involved in the effect of diosgenin against diabetic nephropathy in rat

BackgroundDiabetic nephropathy (DN) is a severe complication of diabetes, which has been increasingly associated with gut microbiota dysbiosis and inflammatory dysregulation.ObjectiveThis study investigates the dual therapeutic potential of diosgenin (DIO), a steroidal sapogenin, in modulating the g...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiang Shanshan, Pan Shu, Hu Xiao, Kudelaidi Kuerban, Zhu Hao, Wang Yujie, Wang Rong, Shi Yuhuan, Yuan Yongfang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
diosgenin
anti-inflammatory
gut microbiota
diabetic nephropathy
NLRP3 inflammasome
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1555849/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundDiabetic nephropathy (DN) is a severe complication of diabetes, which has been increasingly associated with gut microbiota dysbiosis and inflammatory dysregulation.ObjectiveThis study investigates the dual therapeutic potential of diosgenin (DIO), a steroidal sapogenin, in modulating the gut-kidney axis and NLRP3 inflammasome activity in a streptozotocin (STZ)-induced DN rat model.MethodsOral DIO administration (20 mg/kg, 8 weeks) was used to treat the DN rats. The study assessed the effects on metabolic and renal function parameters, renal apoptosis and fibrosis, gut microbiota diversity, and NLRP3 inflammasome activation in the kidney.ResultsDIO treatment ameliorated the progression of DN, improving metabolic and renal function. It attenuated renal apoptosis and fibrosis and restored gut microbiota diversity, particularly enriching the abundance of Lachnospiraceae and Eubacterium. Mechanistically, DIO suppressed NLRP3 inflammasome activation in the kidney, disrupted the LPS-TLR4/NF-κB signaling cascade, and reduced systemic pro-inflammatory cytokines (IL-1β, IL-6).ConclusionDIO is a multitarget agent that addresses both gut microbiota homeostasis and NLRP3-driven inflammation, presenting a novel therapeutic strategy for DN through modulation of the gut-kidney axis.
ISSN:1663-9812

Similar Items